TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Nešković, Mihailo
AU  - Otašević, Petar
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8038
AB  - Abdominal Aortic Aneurysm (AAA) is a degenerative disease of the aortic wall with potentially fatal complications. Open Repair (OR) was considered the gold standard, until the emergence of Endovascular Aneurysm Repair (EVAR), which is less invasive and equally (if not more) effective. As the popularity of endovascular procedures grows, related complications become more evident, with kidney damage being one of them. Although Acute Kidney Injury (AKI) following EVAR is relatively common, its true incidence is still uncertain. Also, there is insufficient data concerning long-term renal outcomes after EVAR, especially with repeated contrast agent exposure. Despite the lack of firm evidence on the effectiveness of individual strategies, it is evident that prevention of AKI following EVAR requires a multifactorial approach. This review focuses on recent findings based on human studies regarding the current evidence of renal impairment after EVAR, its quantification and strategies for its prevention. © 2019 Bentham Science Publishers.
T2  - Current Vascular Pharmacology
T1  - Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair
VL  - 17
IS  - 2
SP  - 133
EP  - 140
DO  - 10.2174/1570161115666171116163203
ER  - 

@article{
author = "Radak, Đorđe J. and Nešković, Mihailo and Otašević, Petar and Isenović, Esma R.",
year = "2019",
abstract = "Abdominal Aortic Aneurysm (AAA) is a degenerative disease of the aortic wall with potentially fatal complications. Open Repair (OR) was considered the gold standard, until the emergence of Endovascular Aneurysm Repair (EVAR), which is less invasive and equally (if not more) effective. As the popularity of endovascular procedures grows, related complications become more evident, with kidney damage being one of them. Although Acute Kidney Injury (AKI) following EVAR is relatively common, its true incidence is still uncertain. Also, there is insufficient data concerning long-term renal outcomes after EVAR, especially with repeated contrast agent exposure. Despite the lack of firm evidence on the effectiveness of individual strategies, it is evident that prevention of AKI following EVAR requires a multifactorial approach. This review focuses on recent findings based on human studies regarding the current evidence of renal impairment after EVAR, its quantification and strategies for its prevention. © 2019 Bentham Science Publishers.",
journal = "Current Vascular Pharmacology",
title = "Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair",
volume = "17",
number = "2",
pages = "133-140",
doi = "10.2174/1570161115666171116163203"
}

Radak, Đ. J., Nešković, M., Otašević, P.,& Isenović, E. R.. (2019). Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair. in Current Vascular Pharmacology, 17(2), 133-140.
https://doi.org/10.2174/1570161115666171116163203

Radak ĐJ, Nešković M, Otašević P, Isenović ER. Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair. in Current Vascular Pharmacology. 2019;17(2):133-140.
doi:10.2174/1570161115666171116163203 .

Radak, Đorđe J., Nešković, Mihailo, Otašević, Petar, Isenović, Esma R., "Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair" in Current Vascular Pharmacology, 17, no. 2 (2019):133-140,
https://doi.org/10.2174/1570161115666171116163203 . .

TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Nešković, Mihailo
AU  - Otašević, Petar
AU  - Isenović, Esma R.
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8040
AB  - Abdominal Aortic Aneurysm (AAA) is a degenerative disease of the aortic wall with potentially fatal complications. Open Repair (OR) was considered the gold standard, until the emergence of Endovascular Aneurysm Repair (EVAR), which is less invasive and equally (if not more) effective. As the popularity of endovascular procedures grows, related complications become more evident, with kidney damage being one of them. Although Acute Kidney Injury (AKI) following EVAR is relatively common, its true incidence is still uncertain. Also, there is insufficient data concerning long-term renal outcomes after EVAR, especially with repeated contrast agent exposure. Despite the lack of firm evidence on the effectiveness of individual strategies, it is evident that prevention of AKI following EVAR requires a multifactorial approach. This review focuses on recent findings based on human studies regarding the current evidence of renal impairment after EVAR, its quantification and strategies for its prevention. © 2019 Bentham Science Publishers.
T2  - Current Vascular Pharmacology
T1  - Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair
VL  - 17
IS  - 2
SP  - 133
EP  - 140
DO  - 10.2174/1570161115666171116163203
ER  - 

@article{
author = "Radak, Đorđe J. and Nešković, Mihailo and Otašević, Petar and Isenović, Esma R.",
year = "2019",
abstract = "Abdominal Aortic Aneurysm (AAA) is a degenerative disease of the aortic wall with potentially fatal complications. Open Repair (OR) was considered the gold standard, until the emergence of Endovascular Aneurysm Repair (EVAR), which is less invasive and equally (if not more) effective. As the popularity of endovascular procedures grows, related complications become more evident, with kidney damage being one of them. Although Acute Kidney Injury (AKI) following EVAR is relatively common, its true incidence is still uncertain. Also, there is insufficient data concerning long-term renal outcomes after EVAR, especially with repeated contrast agent exposure. Despite the lack of firm evidence on the effectiveness of individual strategies, it is evident that prevention of AKI following EVAR requires a multifactorial approach. This review focuses on recent findings based on human studies regarding the current evidence of renal impairment after EVAR, its quantification and strategies for its prevention. © 2019 Bentham Science Publishers.",
journal = "Current Vascular Pharmacology",
title = "Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair",
volume = "17",
number = "2",
pages = "133-140",
doi = "10.2174/1570161115666171116163203"
}

Radak, Đ. J., Nešković, M., Otašević, P.,& Isenović, E. R.. (2019). Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair. in Current Vascular Pharmacology, 17(2), 133-140.
https://doi.org/10.2174/1570161115666171116163203

Radak ĐJ, Nešković M, Otašević P, Isenović ER. Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair. in Current Vascular Pharmacology. 2019;17(2):133-140.
doi:10.2174/1570161115666171116163203 .

Radak, Đorđe J., Nešković, Mihailo, Otašević, Petar, Isenović, Esma R., "Renal Dysfunction Following Elective Endovascular Aortic Aneurysm Repair" in Current Vascular Pharmacology, 17, no. 2 (2019):133-140,
https://doi.org/10.2174/1570161115666171116163203 . .

TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Atanasijević, Igor
AU  - Nešković, Mihailo
AU  - Isenović, Esma R.
PY  - 2019
UR  - http://www.eurekaselect.com/159661/article
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8098
AB  - Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.
T2  - Current Vascular Pharmacology
T1  - The Significance of Pain in Chronic Venous Disease and its Medical Treatment
VL  - 17
IS  - 3
SP  - 291
EP  - 297
DO  - 10.2174/1570161116666180209111826
ER  - 

@article{
author = "Radak, Đorđe J. and Atanasijević, Igor and Nešković, Mihailo and Isenović, Esma R.",
year = "2019",
abstract = "Chronic venous disease (CVeD) is a highly prevalent condition in the general population, and it has a significant impact on quality of life. While it is usually manifested by obvious signs, such as varicose veins and venous ulcers, other symptoms of the disease are less specific. Among the other symptoms, which include heaviness, swelling, muscle cramps and restless legs, pain is the symptom that most frequently compels CVeD patients to seek medical aid. However, there is a substantial discrepancy between pain severity and clinically detectable signs of CVeD, questioned by several opposing studies. Further evaluation is needed to clarify this subject, and to analyse whether pain development predicts objective CVeD progression. General management of CVeD starts with advising lifestyle changes, such as lowering body mass index and treating comorbidities. However, the mainstay of treatment is compression therapy, with the additional use of pharmacological substances. Venoactive drugs proved to be the drugs of choice for symptom alleviation and slowing the progression of CVeD, with micronized purified flavonoid fraction being the most effective one. Interventional therapy is reserved for advanced stages of the disease.",
journal = "Current Vascular Pharmacology",
title = "The Significance of Pain in Chronic Venous Disease and its Medical Treatment",
volume = "17",
number = "3",
pages = "291-297",
doi = "10.2174/1570161116666180209111826"
}

Radak, Đ. J., Atanasijević, I., Nešković, M.,& Isenović, E. R.. (2019). The Significance of Pain in Chronic Venous Disease and its Medical Treatment. in Current Vascular Pharmacology, 17(3), 291-297.
https://doi.org/10.2174/1570161116666180209111826

Radak ĐJ, Atanasijević I, Nešković M, Isenović ER. The Significance of Pain in Chronic Venous Disease and its Medical Treatment. in Current Vascular Pharmacology. 2019;17(3):291-297.
doi:10.2174/1570161116666180209111826 .

Radak, Đorđe J., Atanasijević, Igor, Nešković, Mihailo, Isenović, Esma R., "The Significance of Pain in Chronic Venous Disease and its Medical Treatment" in Current Vascular Pharmacology, 17, no. 3 (2019):291-297,
https://doi.org/10.2174/1570161116666180209111826 . .